GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Beneish M-Score

NAMS (NewAmsterdam Pharma Co NV) Beneish M-Score : 2.09 (As of Mar. 23, 2025)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 2.09 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's Beneish M-Score or its related term are showing as below:

NAMS' s Beneish M-Score Range Over the Past 10 Years
Min: 2.09   Med: 2.09   Max: 2.09
Current: 2.09

During the past 5 years, the highest Beneish M-Score of NewAmsterdam Pharma Co NV was 2.09. The lowest was 2.09. And the median was 2.09.


NewAmsterdam Pharma Co NV Beneish M-Score Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Beneish M-Score Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
- - - - 2.09

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -3.76 - 2.09

Competitive Comparison of NewAmsterdam Pharma Co NV's Beneish M-Score

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NewAmsterdam Pharma Co NV's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Beneish M-Score falls into.



NewAmsterdam Pharma Co NV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of NewAmsterdam Pharma Co NV for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 3.5026+0.528 * 1+0.404 * 1.0457+0.892 * 3.2337+0.115 * 2.2722
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5789+4.679 * -0.000975-0.327 * 0.8618
=2.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was $21.31 Mil.
Revenue was 12.772 + 29.111 + 2.279 + 1.401 = $45.56 Mil.
Gross Profit was 12.772 + 29.111 + 2.279 + 1.401 = $45.56 Mil.
Total Current Assets was $863.41 Mil.
Total Assets was $864.62 Mil.
Property, Plant and Equipment(Net PPE) was $0.67 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.11 Mil.
Selling, General, & Admin. Expense(SGA) was $70.45 Mil.
Total Current Liabilities was $106.92 Mil.
Long-Term Debt & Capital Lease Obligation was $0.20 Mil.
Net Income was -92.177 + -16.647 + -39.007 + -93.767 = $-241.60 Mil.
Non Operating Income was -53.433 + 3.912 + 8.698 + -41.368 = $-82.19 Mil.
Cash Flow from Operations was -37.481 + -12.502 + -53.979 + -54.602 = $-158.56 Mil.
Total Receivables was $1.88 Mil.
Revenue was 0.803 + 2.941 + 1.717 + 8.629 = $14.09 Mil.
Gross Profit was 0.803 + 2.941 + 1.717 + 8.629 = $14.09 Mil.
Total Current Assets was $346.79 Mil.
Total Assets was $347.10 Mil.
Property, Plant and Equipment(Net PPE) was $0.10 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.05 Mil.
Selling, General, & Admin. Expense(SGA) was $37.63 Mil.
Total Current Liabilities was $49.90 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(21.305 / 45.563) / (1.881 / 14.09)
=0.467594 / 0.133499
=3.5026

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(14.09 / 14.09) / (45.563 / 45.563)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (863.413 + 0.673) / 864.62) / (1 - (346.791 + 0.101) / 347.097)
=0.000618 / 0.000591
=1.0457

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=45.563 / 14.09
=3.2337

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.049 / (0.049 + 0.101)) / (0.113 / (0.113 + 0.673))
=0.326667 / 0.143766
=2.2722

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(70.446 / 45.563) / (37.633 / 14.09)
=1.546123 / 2.670901
=0.5789

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.202 + 106.918) / 864.62) / ((0 + 49.897) / 347.097)
=0.123893 / 0.143755
=0.8618

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-241.598 - -82.191 - -158.564) / 864.62
=-0.000975

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

NewAmsterdam Pharma Co NV has a M-score of 2.09 signals that the company is likely to be a manipulator.


NewAmsterdam Pharma Co NV Beneish M-Score Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.